otenabant
Small moleculeexperimental
Otenabant (CP-945,598) is a drug that acts as a potent and highly selective CB1 antagonist. It was developed by Pfizer for the treatment of obesity, but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant. — Wikipedia
Clinical trial activity
13 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
4
Phase 3
5
Phase 4
0
Earliest trial started Mar 1, 2005 (NCT00134199)
Timeline
Indications
Mechanism of action
- Cannabinoid CB1 receptorANTAGONIST
CNR1 antagonist
Development Discontinuedbecause of potential serious side effects linked to targetting of CNR1 (http://en.wikipedia.org/wiki/Otenabant).
Chemistry & pharmacology
Loading structure…
SMILES
CCNC1(C(N)=O)CCN(c2ncnc3c2nc(-c2ccccc2Cl)n3-c2ccc(Cl)cc2)CC1- Mol. weight
- 510.43 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOtenabant ↗
- ChEMBLCHEMBL562668 ↗
Also known as
- 1-(9-(4-chlorophenyl)-8-(2-chlorophenyl)-9h-purin-6-yl)-4-ethylaminopiperidine-4-carboxylic acid amide
- cp945598
- cp 945598
- cp-945598
- cp-945598
- cp-945598
- cp-945598
- cp-945598
- cp-945,598
- cp-945,598
- cp-945598-01
- cp-945598-01
- otenabant
- otenabant
- otenabant
- otenabant hcl
- otenabant hcl
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01517100 | Phase 1 | Jan 2, 2012 | National Institute on Aging (NIA) |
| NCT01133730 | N/A | Aug 1, 2010 | University of Toronto |
| NCT00706537 | Phase 1 | Jul 1, 2008 | Pfizer |
| NCT00644839 | Phase 1 | Apr 1, 2008 | Pfizer |
| NCT00645021 | Phase 1 | Apr 1, 2008 | Pfizer |
| NCT00483171 | Phase 3 | Jan 1, 2008 | Pfizer |
| NCT00472836 | Phase 1 | Jun 1, 2007 | Pfizer |
| NCT00645216 | Phase 1 | Jun 1, 2007 | Pfizer |
| NCT00645463 | Phase 1 | Mar 1, 2007 | Pfizer |
| NCT00396448 | Phase 3 | Feb 1, 2007 | Pfizer |
| NCT00391196 | Phase 3 | Nov 1, 2006 | Pfizer |
| NCT00375401 | Phase 3 | Oct 1, 2006 | Pfizer |
| NCT00134199 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2005 | Pfizer |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 11 | 11 | 2 | 2005 |
| National Institute on Aging (NIA) | Government | 1 | 1 | 1 | 2012 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2010 |
3 organizations
Page 1 / 1